Disease pathology signatures in a mouse model of Mucopolysaccharidosis type IIIB

Ralitsa Petrova1, Abhijeet R Patil2, Vivian Trinh3

  • 1Biologics Discovery Science, Teva Pharmaceutical Industries Ltd, Redwood City, CA, USA. ralitsaip@gmail.com.

Scientific Reports
|October 4, 2023
PubMed

Insights

Mucopolysaccharidosis type IIIB (MPS IIIB), a rare childhood disease, involves heparan sulfate buildup due to a missing enzyme. This study characterized a mouse model to understand disease mechanisms and find biomarkers.

Area of Science:

  • Biochemistry
  • Genetics
  • Neuroscience

Background:

  • Mucopolysaccharidosis type IIIB (MPS IIIB) is a rare, severe childhood lysosomal storage disease.
  • It results from a deficiency in the enzyme α-N-acetylglucosaminidase, leading to heparan sulfate accumulation.
  • This accumulation causes neuroinflammation and severe cognitive impairment, necessitating research into pathophysiology and treatments.

Purpose of the Study:

  • To systematically characterize a classical mouse model of MPS IIIB.
  • To validate known phenotypes and explore novel disease mechanisms.
  • To identify potential biomarkers for MPS IIIB.

Main Methods:

  • Utilized histological, biochemical, proteomic, and behavioral assays.
  • Examined MPS IIIB mice during pre-symptomatic and early symptomatic disease phases.
  • Conducted a systematic characterization of the MPS IIIB mouse model.

Main Results:

  • Validated previously described phenotypes in the MPS IIIB mouse model.
  • Provided insights into new mechanisms driving MPS IIIB pathology.
  • Identified potential biomarkers for MPS IIIB.

Conclusions:

  • This study deepens the understanding of MPS IIIB pathology.
  • Characterization of the mouse model serves as a resource for future research.
  • Findings contribute to the development of therapeutic strategies for this rare disease.

Related Concept Videos